Lightning Flashes As Boston Scientific Takes Over Penumbra For $14.5 Billion
Investors·2026-01-15 16:03

Core Viewpoint - Boston Scientific (BSX) is acquiring Penumbra (PEN) for $14.5 billion, or $374 per share, which will enhance Boston Scientific's presence in the cardiovascular sector [1] Group 1: Acquisition Details - The acquisition price of $14.5 billion represents a significant investment for Boston Scientific [1] - Penumbra specializes in mechanical thrombectomy and neurovascular fields, focusing on treatments for conditions such as pulmonary embolism, stroke, deep vein thrombosis, acute limb ischemia, and heart-related issues [1] Group 2: Market Reaction - Following the announcement, Boston Scientific's shares experienced a decline before the market opened, while Penumbra's stock saw an increase [1]